The AIM-listed medical imaging group said Shaw is a highly experienced NHS executive with a strong track record in strategy development and international relations.
READ: Feedback Medical unit signs new 2-year deal to support Royal Papworth Hospital’s scan analysis
In November 2013, he was appointed as medical director of Healthcare UK, part of the Department of International Trade, to lead the NHS International Development Team.
Prior to this, Shaw was a medical director in the NHS for over 15 years, latterly at North West London Hospitals Trust, and previously at Royal Berkshire Foundation Trust and Hammersmith Hospitals Trust.
He has also held national roles as non-executive of the NHS Litigation Authority and previously as the first chairman of the National Patient Safety Agency.
David Crabb, Feedback chief executive, said: "With a unique combination of clinical and international engagement experience, Professor Shaw brings a highly complementary skill-set to the team. His clinical input, together with Dr Balaji Ganeshan's market expertise, will underpin our product development strategy following the first CE marked release of the TexRAD technology. Furthermore, Professor Shaw's international reach will be invaluable as we continue to pursue opportunities to increase TexRAD and Cadran platform technology sales globally."
Rory Shaw, medical director of Feedback Medical Limited, said: "The TexRAD technology provides a way of obtaining a new level of information about cancers by using Artificial Intelligence to undertake an in-depth analysis of CT scans and other images. The next exciting phase is to understand how this new information can be used in the clinical care of patients with diseases such as lung cancer, to enable better disease staging and thus to enable more effective cancer treatment."
Feedback shares were up 5.5% at 2.88p.
-- Adds share price --